General Information:

Id: 2,038 (click here to show other Interactions for entry)
Diseases: Diabetes mellitus, type II - [OMIM]
Insulin resistance
Rattus norvegicus
BTO:0002809 L-6 myoblast cell
article
Reference: Wei Y et al.(2008) Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am. J. Physiol. Endocrinol. Metab. 294: E345-E351 [PMID: 18073321]

Interaction Information:

Comment ANG II treatment of L6 myotubes induced NF-kappaB activation and TNF-alpha production and decreased insulin-stimulated Akt activation and GLUT-4 glucose transporter translocation to plasma membranes. These effects were markedly diminished by treatment of myotubes with valsartan, the antioxidant N-acetylcysteine, NADPH oxidase-inhibiting peptide (gp91 ds-tat), or NF-kappaB inhibitor (MG-132).
Formal Description
Interaction-ID: 16214

gene/protein

Angiotensin II

increases_activity of

complex/PPI

NF-kappaB complex

in skeletal muscle
Comment ANG II treatment of L6 myotubes induced NF-kappaB activation and TNF-alpha production and decreased insulin-stimulated Akt activation and GLUT-4 glucose transporter translocation to plasma membranes. These effects were markedly diminished by treatment of myotubes with valsartan, the antioxidant N-acetylcysteine, NADPH oxidase-inhibiting peptide (gp91 ds-tat), or NF-kappaB inhibitor (MG-132).
Formal Description
Interaction-ID: 16216

gene/protein

Angiotensin II

increases_expression of

gene/protein

TNF

in skeletal muscle
Drugbank entries Show/Hide entries for TNF
Comment ANG II treatment of L6 myotubes induced NF-kappaB activation and TNF-alpha production and decreased insulin-stimulated Akt activation and GLUT-4 glucose transporter translocation to plasma membranes. These effects were markedly diminished by treatment of myotubes with valsartan, the antioxidant N-acetylcysteine, NADPH oxidase-inhibiting peptide (gp91 ds-tat), or NF-kappaB inhibitor (MG-132).
Formal Description
Interaction-ID: 16217

gene/protein

Angiotensin II

decreases_activity of

gene/protein

AKT1

in skeletal muscle; if stimulated by insulin
Drugbank entries Show/Hide entries for AKT1
Comment ANG II treatment of L6 myotubes induced NF-kappaB activation and TNF-alpha production and decreased insulin-stimulated Akt activation and GLUT-4 glucose transporter translocation to plasma membranes. These effects were markedly diminished by treatment of myotubes with valsartan, the antioxidant N-acetylcysteine, NADPH oxidase-inhibiting peptide (gp91 ds-tat), or NF-kappaB inhibitor (MG-132).
Formal Description
Interaction-ID: 16218

gene/protein

Angiotensin II

decreases transport of

gene/protein

SLC2A4

to the plasma membrane, in skeletal muscle; if stimulated by insulin